The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world experience with sunitinib treatment in patients with metastatic renal cell carcinoma: Clinical outcome according to risk score.
 
Manuela Schmidinger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Exelis; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Exelis; Novartis; Pfizer; Roche
 
Camillo Porta
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Pfizer
Research Funding - Pfizer
 
Stephane Oudard
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer
 
Gwénaël Dénéchère
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Yves Brault
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Lucile Serfass
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nuno Matos Costa
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech